Shaperon, which develops the atopic dermatitis treatment 'Nugel,' is rising slightly in the early hours of trading on the 10th. This appears to be due to expectations of technology transfer. (Related article☞ “A game changer that overcomes the limits of atopic treatments… Aiming for technology export within the year”)
Shaperon shares are trading in the 3,200 won range, up slightly from the previous trading day at 9:02 a.m. on this day. The news of a technology transfer for Nugel within the year seems to have stimulated investor sentiment.
Seong Seung-yong, the representative of Shaperon, told ChosunBiz in an interview, “We have proven the safety and efficacy of Nugel in patients with moderate to severe atopic dermatitis through the Phase 2 Part 1 trial in the U.S., and based on this, we are discussing technology transfer with several global pharmaceutical companies.”
Seong added, “We are currently conducting follow-up meetings with companies with whom we signed non-disclosure agreements at the JP Morgan Healthcare Conference in January,” noting, “We are actively negotiating technology transfer with 11 global pharmaceutical corporations, including leading multinational companies in the dermatology institutional sector, and we are currently conducting technical due diligence with some of these companies.”
Shaperon is a company founded by Professor Seong Seung-yong of Seoul National University College of Medicine as an on-campus venture in 2008 and was listed on the Korea Securities Dealers Automated Quotations (KOSDAQ) in October 2022. In addition to Nugel, it is also pursuing the development of new drugs in various therapeutic areas such as hair loss and anti-aging. Last year, the company established an artificial intelligence (AI)-based drug development platform.